Skip to main content
Clinical Trials/DRKS00026128
DRKS00026128
Completed
Not Applicable

Real world extension study in patients with atopic dermatitis who participated in previous tralokinumab trials - Observational ECZTEND

EO Pharma A/S0 sites63 target enrollmentOctober 12, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
L20.9
Sponsor
EO Pharma A/S
Enrollment
63
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 12, 2021
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
EO Pharma A/S

Eligibility Criteria

Inclusion Criteria

  • Adult patients eligible for treatment with tralokinumab according to the national, approved label where the decision to prescribe tralokinumab has been made prior to and independently of enrolment in the study.
  • \-Signed and dated informed consent.
  • \-Participated in the ECZTEND clinical trial and decision to continue tralokinumab treatment with commercially available drug.

Exclusion Criteria

  • \-Participation in the active treatment phase of a clinical trial.
  • \-Previous enrolment in the study.
  • \-Contraindications according to the label.

Outcomes

Primary Outcomes

Not specified

Similar Trials